DONATE TODAY
To Increase Patient Access
End Brain Cancer Mobile App to download your number one tool for navigating this disease.

May 17, 2023

Imvax Immunotherapy Clinical Study

ATTENTION:

We wanted to make you aware of a new Phase 2b Clinical Study with a Combination Immunotherapy for Newly Diagnosed Patients with Glioblastoma (GBM).

Imvax is a clinical-stage biotechnology company with a unique platform technology, Goldspire™, focused on delivering personalized, whole tumor-derived immunotherapies across a range of solid tumors. Imvax’s most advanced program, IGV-001, is currently being evaluated in a Phase 2b clinical trial in newly diagnosed glioblastoma patients (NCT04485949). Imvax’s portfolio also includes several other programs designed to stimulate a patient’s immune system against the entire antigen signature of their tumor. Imvax is headquartered in Philadelphia, PA.

For additional information on the Imvax Immunotherapy Clinical Study, please visit www.imvax.com and follow @imvax_inc on Twitter and LinkedIn, contact Madhavi Diwanji at 267-900-4110 or at m.diwanji@imvax.com  OR please contact www.EndBrainCancer.org, fill out our short “Advocacy & Patient Inquiry Form” on our website, or call EBCI’s Program & Trial/Study Manager at 425-436-8688 or email us at WeCare@EndBrainCancer.org.  We are here to help.

Dellann

Dellann Elliott Mydland
President & Board Chair

The EndBrainCancer Initiative | Chris Elliott Fund
Dellann@EndBrainCancer.org

www.EndBrainCancer.org

ENDBRAINCANCER INITIATIVE | CHRIS ELLIOTT FUND

Enhancing patient outcomes by expanding FDA-approved treatment modalities and fueling research in the pharma/bio/life sciences, device & diagnostic industries and by closing the existing GAP from initial diagnosis to IMMEDIATE AND EXPANDED ACCESS to specialists, researchers, advanced & innovative treatments, clinical trials and critical care with the ultimate goal of improving patient outcomes through updating and improving WHO & NCCN Guidelines and clinical practices related to Standard of Care for brain cancer patients.

TAX ID:26-2185614
DONATE
corporate partners
upcoming events
resources
About us
envelopephonemap-markerpointer-right
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram